NCT01806259View on ClinicalTrials.gov

Ketorolac in Breast Cancer Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

September 30, 2018

Conditions
Curative Breast Cancer SurgeryInflammatory Positive/Negative StatusPre Surgical Incision Administration
Interventions
DRUG

Ketorolac 30 mg IV

Active drug

DRUG

Placebos

Placebo looking like the Active drug

Trial Locations (1)

1200

Cliniques universitaires Saint-Luc, Brussels

All Listed Sponsors
collaborator

Anticancer Fund, Belgium

OTHER

lead

Université Catholique de Louvain

OTHER

NCT01806259 - Ketorolac in Breast Cancer Surgery | Biotech Hunter | Biotech Hunter